麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

法國Polyplus-transfection 
Polyplus-transfection SA 是一家生物科技公司，致力于在研究、生物生產(chǎn)和治療領(lǐng)域開發(fā)、推廣和銷售創(chuàng)新型核酸體內(nèi)、體外和離體傳輸解決方案。該公司靠近法國東部的斯特拉斯堡大學(xué) (University of Strasbourg)，自2002年起通過 ISO 9001 認(rèn)證，通過全球分銷商網(wǎng)絡(luò)提供其專有的多種基因、寡核苷酸和 siRNA 轉(zhuǎn)染試劑。在世界范圍內(nèi)，越來越多的臨床試驗(yàn)采用 Polyplus 試劑。此外，Polyplus-transfection 還擁有多項(xiàng)專利和許可證，包括獨(dú)創(chuàng)的治療 siRNA 傳輸方法。

Polyplus-transfection是一家生命科學(xué)公司，致力于轉(zhuǎn)染試劑研發(fā)和銷售。其中包括基因，寡核苷酸和SiRNA的體內(nèi)和體外轉(zhuǎn)染，以及蛋白質(zhì)和抗體的體外轉(zhuǎn)染。
Polyplus-transfection公司的主要使命是擔(dān)當(dāng)科研實(shí)驗(yàn)室、生物技術(shù)公司和制藥公司可靠的技術(shù)合作伙伴。公司的出發(fā)點(diǎn)是為科研者提供高質(zhì)量的研究工具和技術(shù)支持。鑒于Polyplus-transfection公司的發(fā)展，產(chǎn)品，以及銷售情況，2002年，公司被授予國際標(biāo)準(zhǔn)ISO 9001：2000證書。
Polyplus產(chǎn)品：
jetPEI：轉(zhuǎn)染多種已經(jīng)建系的貼壁細(xì)胞、懸浮細(xì)胞及原代細(xì)胞
INTERFERin：體外siRNA轉(zhuǎn)染試劑
in vivo jetPEI：體內(nèi)DNA、siRNA轉(zhuǎn)染試劑
PULSin：體外蛋白、抗體轉(zhuǎn)染試劑
jetPEI-Macrophage：轉(zhuǎn)染巨噬細(xì)胞和樹突狀細(xì)胞
jetPEI-Hepatocyte：轉(zhuǎn)染肝實(shí)質(zhì)細(xì)胞
jetPEI-RGD：轉(zhuǎn)染上皮及內(nèi)皮細(xì)胞
jetPEI-HUVEC：轉(zhuǎn)染人臍靜脈內(nèi)皮細(xì)胞
jetPEI-FluoF : 熒光素標(biāo)記的jetPEI
jetPEI-FluoR : 四甲基羅丹明標(biāo)記的jetPEI
in vivo-jetPEI-FluoF : 熒光素標(biāo)記的in vivo-jetPEI
in vivo-jetPEI-FluoR : 四甲基羅丹明標(biāo)記的in vivo-jetPEI
in vitro-jetPEI-Biotin
in vivo-jetPEI-Biotin

Polyplus-transfection is a research-focused biotechnology company developing and marketing innovative solutions for transfection and therapies based on nucleic acid delivery. 

Technology

Transfection allows the introduction of nucleic acids, such as a gene or small interfering RNA (siRNA), into cells using chemical compounds. The technique is widely used in experimental research and in protein production.
Introducing a gene into a cell nucleus triggers the expression of the corresponding protein. Conversely, transferring siRNA will block the production of a protein.
Inappropriate gene expression is the root cause of numerous diseases. As a result, the ability to control those genes through gene therapy or RNA interference opens up new therapeutic approaches where efficient intra-cellular drug transfer is key to success.

Research & Development

Using its know-how in nucleic acid delivery, the R&D department at Polyplus-transfection is focused on the development of innovative synthetic compounds designed to take account of the latest advances in the transfer of biomolecules, especially the in vivo delivery of small interfering RNA. Polyplus-transfection is one of the technology leaders in the transfection market.
Polyplus-transfection has established a number of R&D partnerships with biotechnology companies involved in therapeutics. It also plays an active role in European research networks such as GIANT (Gene therapy, and Integrated Approach to Neoplastic Treatment) and RIGHT (RNA Interference Technology as Human Therapeutic Tool).
Polyplus-transfection recently extended its field of expertise to the development of new cationic oligonucleotides, ZNA?, for molecular biology and diagnostics.

Product Portfolio

Polyplus-transfection has been selling its products and services through an international distribution network since 2001. Its customers include biotechnology companies, big pharma and research laboratories. The company established a sales subsidiary in the USA in 2006.
The company also offers high quality consultancy and personalized scientific assistance. Polyplus-transfection has given a high priority to quality management since 2002 when it acquired the ISO 9001:2000 certification.
Polyplus-transfection markets transfection agents for research:
o jetPEI?: in vitro gene transfection
o in vivo-jetPEI?: in vivo nucleic acid transfection
o Fecturin? : protein and virus production in synthetic media
o INTERFERin?: in vitro siRNA transfection
o FectoFly?: in vitro transfection in insect cells
o PULSin?: in vitro delivery of proteins, antibodies and peptides
Polyplus-transfection also offers GMP-compliant reagents. The company has acquired a widely-acknowledged expertise in the regulatory and technical issues regarding clinical trials using its products. Such trials are currently being carried out in Israel and the USA (cancer therapeutics) and in Hungary, Sweden and Germany (HIV immune therapy).

Current developments

o Setting up of the Polyplus in vivo Consortium, an international network, run by Polyplus-transfection, for scientists and clinicians using Polyplus-transfection compounds in gene therapy. The network aims to encourage and accelerate the development of new clinical projects.
o Development of a novel design of siRNA in order to improve siRNA delivery in vivo, the “STICKY SIRNA?”. By including longer overhangs, the STICKY SIRNA? (ssiRNA?) are able to form concatemers in the presence of in vivo-jetPEI?, thereby mimicking the structure of DNA and thus enhancing siRNA delivery (Bolcato-Bellemin (2007) PNAS 104:16050).
o Development of a new class of modified oligonucleotides, ZNA?, which show a greater affinity for nucleic acids than standard oligonucleotides. By enhancing the sensitivity and the efficiency of hybridization, these versatile ZNA? are new promising tools for nucleic acid detection methods and for molecular diagnostic applications.